Published in Eur J Gastroenterol Hepatol on January 01, 2006
How wasting is saving: weight loss at altitude might result from an evolutionary adaptation. Bioessays (2014) 1.45
Lower obesity rate during residence at high altitude among a military population with frequent migration: a quasi experimental model for investigating spatial causation. PLoS One (2014) 0.98
Body mass regulation at altitude. Eur J Gastroenterol Hepatol (2006) 0.98
Exercise training during normobaric hypoxic confinement does not alter hormonal appetite regulation. PLoS One (2014) 0.87
Physiology and pathophysiology at high altitude: considerations for the anesthesiologist. J Anesth (2009) 0.86
Nutritional strategies for the preservation of fat free mass at high altitude. Nutrients (2014) 0.79
[Effects of acute altitude exposure: which altitude can be tolerated?]. Wien Med Wochenschr (2010) 0.78
Appetite at high altitude: an fMRI study on the impact of prolonged high-altitude residence on gustatory neural processing. Exp Brain Res (2010) 0.76
Increased protein intake in military special operations. J Nutr (2013) 0.75
Non-hematopoietic effects of endogenous erythropoietin on lean mass and body weight regulation. Obesity (Silver Spring) (2016) 0.75
Serum irisin and myostatin levels after 2 weeks of high-altitude climbing. PLoS One (2017) 0.75
Does hypoxia play a role in the development of sarcopenia in humans? Mechanistic insights from the Caudwell Xtreme Everest Expedition. Redox Biol (2017) 0.75
Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut (2011) 4.79
Mucosal healing in inflammatory bowel diseases: a systematic review. Gut (2012) 3.02
Use of endoscopy for management of acute upper gastrointestinal bleeding in the UK: results of a nationwide audit. Gut (2010) 2.82
IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med (2011) 2.74
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol (2010) 1.74
TUCAN (CARD8) genetic variants and inflammatory bowel disease. Gastroenterology (2006) 1.73
A common CTLA4 haplotype associated with coeliac disease. Eur J Hum Genet (2005) 1.65
Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. Trials (2007) 1.62
Obstructing giant post-inflammatory polyposis in ulcerative colitis: Case report and review of the literature. J Crohns Colitis (2008) 1.28
A basal gradient of Wnt and stem-cell number influences regional tumour distribution in human and mouse intestinal tracts. Gut (2012) 1.16
Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol (2011) 1.16
The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol (2011) 1.15
The pattern and outcome of acute severe colitis. J Crohns Colitis (2010) 1.06
Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum (2006) 1.01
The role of CMV in steroid-resistant ulcerative colitis: A systematic review. J Crohns Colitis (2009) 1.00
Medical management of Crohn's disease. BMJ (2008) 0.97
Restrictive vs liberal blood transfusion for acute upper gastrointestinal bleeding: rationale and protocol for a cluster randomized feasibility trial. Transfus Med Rev (2013) 0.95
Prevalence, management, and outcomes of patients with coagulopathy after acute nonvariceal upper gastrointestinal bleeding in the United Kingdom. Transfusion (2012) 0.89
Biosimilars in IBD: hope or expectation? Gut (2013) 0.88
Thiopurine therapy: when to start and when to stop. Eur J Gastroenterol Hepatol (2003) 0.86
Red blood cell transfusion practice in patients presenting with acute upper gastrointestinal bleeding: a survey of 815 UK clinicians. Transfusion (2011) 0.86
What is the optimal treatment for anemia in inflammatory bowel disease? Curr Drug Deliv (2012) 0.85
Risk for colorectal neoplasia in patients with colonic Crohn's disease and concomitant primary sclerosing cholangitis. Clin Gastroenterol Hepatol (2011) 0.85
The European consensus on ulcerative colitis: new horizons? Gut (2008) 0.83
Comparison between prospective and retrospective evaluation of Crohn's disease activity index. Am J Gastroenterol (2005) 0.82
How to manage the infectious risk under anti-TNF in inflammatory bowel disease. Curr Drug Targets (2010) 0.79
Therapy of ulcerative colitis: state of the art. Curr Opin Gastroenterol (2008) 0.79
Conventional drug therapy for inflammatory bowel disease. Scand J Gastroenterol (2015) 0.78
Recurrent posterior scleritis and orbital myositis as extra-intestinal manifestations of Crohn's disease: Case report and systematic literature review. J Crohns Colitis (2008) 0.77
Role of tumor necrosis factor in Crohn's disease. Curr Opin Investig Drugs (2002) 0.77
An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial. J Crohns Colitis (2008) 0.76
Therapeutic inhibitors of tumor necrosis factor in Crohn's disease. Curr Opin Investig Drugs (2002) 0.76
An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis based on results from randomised controlled trial. J Crohns Colitis (2009) 0.76
Acute upper gastrointestinal bleeding: identifying low risk patients. Gut (2012) 0.75
Causality and Chance in the Development of Cancer. N Engl J Med (2015) 0.75
IBD and IBS: novel mechanisms and future practice. Preface. Dig Dis (2010) 0.75
Erratum: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med (2017) 0.75